GSK India Managing Director Hasit Joshipura On What Lies Ahead For India’s Largest Multinational Drug Company: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline India Managing Director Hasit Joshipura is known as one of the most aggressive multinational pharma directors in India in terms of expansion strategy. Some top GSK officials say he was brought in at the helm with the task of making GSK sharper in its marketing approach. Joshipura presented those capabilities in his earlier stint as the managing director at Johnson & Johnson India. Joshipura sat down with PharmAsia News' India bureau to discuss what lies ahead for India's largest multinational drug company.
You may also be interested in...
GSK India Managing Director Hasit Joshipura On Business Dynamics In India, Tiered Pricing And Approaches To Rural Markets: An Interview With PharmAsia News (Part 2 Of 2)
Hasit Joshipura, GlaxoSmithKline's India Managing Director is unfazed by the recent mega-deal that Abbott struck with Piramal Healthcare - catapulting the U.S. giant to the number one slot in India with a market share of nearly 7 percent.
GSK India Managing Director Hasit Joshipura On Business Dynamics In India, Tiered Pricing And Approaches To Rural Markets: An Interview With PharmAsia News (Part 2 Of 2)
Hasit Joshipura, GlaxoSmithKline's India Managing Director is unfazed by the recent mega-deal that Abbott struck with Piramal Healthcare - catapulting the U.S. giant to the number one slot in India with a market share of nearly 7 percent.
GSK India Managing Director Hasit Joshipura On Business Dynamics In India, Tiered Pricing And Approaches To Rural Markets: An Interview With PharmAsia News
Joshipura is unfazed by the recent deal between Abbott and Piramal Healthcare and its potential impact on GSK's business in India.